Pharmacists expand access to reproductive heaLthcare: PEARL study protocol.


Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
01 Apr 2019
Historique:
received: 19 02 2019
accepted: 24 03 2019
entrez: 3 4 2019
pubmed: 3 4 2019
medline: 16 5 2019
Statut: epublish

Résumé

In 2016, Oregon became the first of eight states to allow pharmacists to directly prescribe hormonal contraception (HC), including the pill, patch, or ring, without a clinic visit. In the two years following this policy change, the majority of ZIP codes across the state of Oregon had a pharmacist certified to prescribe HC. We will utilize complementary methodologies to evaluate the effect of this policy change on convenient access to contraception (cost, supply dispensed), safety, contraceptive continuation and unintended pregnancy rates. We will conduct a prospective clinical cohort study to directly measure the impact of provider type on contraceptive continuation and to understand who is accessing hormonal contraception directly from pharmacists. We will concurrently conduct a retrospective analysis using medical claims data to evaluate the state-level effect of the policy. We will examine contraceptive continuation rates, incident pregnancy, and safety measures. The combination of these methodologies allows us to examine key woman-level factors, such as pregnancy intention and usual place of care, while also estimating the impact of the pharmacist prescription policy at the state level. Pharmacist prescription of HC is emerging nationally as a strategy to reduce unintended pregnancy. This study will provide data on the effect of this practice on convenient access to care, contraceptive safety and continuation rates.

Sections du résumé

BACKGROUND BACKGROUND
In 2016, Oregon became the first of eight states to allow pharmacists to directly prescribe hormonal contraception (HC), including the pill, patch, or ring, without a clinic visit. In the two years following this policy change, the majority of ZIP codes across the state of Oregon had a pharmacist certified to prescribe HC.
METHODS METHODS
We will utilize complementary methodologies to evaluate the effect of this policy change on convenient access to contraception (cost, supply dispensed), safety, contraceptive continuation and unintended pregnancy rates. We will conduct a prospective clinical cohort study to directly measure the impact of provider type on contraceptive continuation and to understand who is accessing hormonal contraception directly from pharmacists. We will concurrently conduct a retrospective analysis using medical claims data to evaluate the state-level effect of the policy. We will examine contraceptive continuation rates, incident pregnancy, and safety measures. The combination of these methodologies allows us to examine key woman-level factors, such as pregnancy intention and usual place of care, while also estimating the impact of the pharmacist prescription policy at the state level.
DISCUSSION CONCLUSIONS
Pharmacist prescription of HC is emerging nationally as a strategy to reduce unintended pregnancy. This study will provide data on the effect of this practice on convenient access to care, contraceptive safety and continuation rates.

Identifiants

pubmed: 30935394
doi: 10.1186/s12913-019-4038-9
pii: 10.1186/s12913-019-4038-9
pmc: PMC6444429
doi:

Substances chimiques

Contraceptive Agents, Female 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

207

Subventions

Organisme : Laura and John Arnold Foundation
ID : 0

Références

Contraception. 2006 May;73(5):501-6
pubmed: 16627034
Contraception. 2006 Dec;74(6):463-70
pubmed: 17157103
Am J Obstet Gynecol. 2010 Mar;202(3):214-20
pubmed: 20207237
Stat Sci. 2010 Feb 1;25(1):1-21
pubmed: 20871802
Obstet Gynecol. 2011 Mar;117(3):551-7
pubmed: 21343757
Obstet Gynecol. 2011 Mar;117(3):558-65
pubmed: 21343758
Perspect Sex Reprod Health. 2011 Sep;43(3):173-80
pubmed: 21884385
Contraception. 2012 Oct;86(4):376-82
pubmed: 22520645
Biometrics. 2013 Sep;69(3):633-40
pubmed: 23724948
Am J Public Health. 2013 Oct;103(10):1772-9
pubmed: 23948010
Am J Obstet Gynecol. 2014 Jun;210(6):526.e1-9
pubmed: 24495671
Respirology. 2014 Jul;19(5):625-35
pubmed: 24889820
Obstet Gynecol. 2016 Jul;128(1):168-70
pubmed: 27275808
J Am Pharm Assoc (2003). 2018 Nov - Dec;58(6):608-613
pubmed: 30190201

Auteurs

Maria I Rodriguez (MI)

Department of Obstetrics and Gynecology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, UHN 50, Portland, OR, 97239, USA. rodrigma@ohsu.edu.

Blair G Darney (BG)

Department of Obstetrics and Gynecology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, UHN 50, Portland, OR, 97239, USA.

Alison B Edelman (AB)

Department of Obstetrics and Gynecology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, UHN 50, Portland, OR, 97239, USA.

Kimberly Yee (K)

Center for Health Systems Effectiveness, Oregon Health &Science University, Portland, USA.

Lorinda B Anderson (LB)

College of Pharmacy, Oregon State University, Corvallis, USA.

K John McConnell (KJ)

Center for Health Systems Effectiveness, Oregon Health &Science University, Portland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH